P809 - DOES THE GUT MICROBIOME PLAY A ROLE IN THE RESPONSE TO GLP-2 ANALOGUE TREATMENT IN SHORT BOWEL SYNDROME?

P809

DOES THE GUT MICROBIOME PLAY A ROLE IN THE RESPONSE TO GLP-2 ANALOGUE TREATMENT IN SHORT BOWEL SYNDROME?

M. Bourgin^1,*, A. Garrigues¹, A. Dumay¹, L. Ribeiro-Parenti ^1,2, L. LA¹, F. Joly^1,3, A. Bado¹, M. Thomas⁴, N. Kapel⁵, M. Le Gall¹, J. Le Behec-Le Bihan^1,6

¹Universite Paris Cite, UMR-S1149, Centre de recherche sur l'inflammation, ²Service de chirurgie Générale Oesogastrique et Bariatrique , AP-HP, Hôpital Bichat -Claude Bernard, Paris, ³Department of gastroenterology, IBD and nutrition Support, , AP-HP, CRMR MarDi, Hôpital Beaujon, Clichy, ⁴ Université Paris-Saclay, UMR1319 - Micalis Institute, Institut National de Recherche pour l'Agriculture, l'alimentation et l'environnement (INRAE), AgroParisTech, Jouy-en-Josas, ⁵ Service de Coprologie fonctionnelle, Paris, France. 6Sorbonne Université, AP-HP, Hôpital de la Pitié-Salpêtrière-Charles Foix, AP-HP, Hôpital de la Pitié-Salpêtrière-Charles Foix,, ⁶Sorbonne Université,, AP-HP, Hôpital de la Pitié-Salpêtrière-Charles Foix, Paris, France

Rationale: GLP-2 is critical for controlling gut function. Its analogues have been developed to improve 
nutrient absorption in patients with short bowel syndrome (SBS). The response to GLP-2 analogues in 
patients is markedly heterogeneous. Studies have shown that the microbiome has an impact on the 
effectiveness of therapies. We hypothesise that the gut microbiome plays a role in response to GLP-2 
analogue treatment in a rat model of SBS.

Methods: Wistar rats underwent either 80% resection of the small bowel and right colon and received 
(SBS-GLP2) or not (SBS) a GLP-2 analogue treatment for 3 weeks. Moreover, 16 Wistar rats treated 
with broad-spectrum antibiotics underwent this intestinal resection and received (SBS-ATB-GLP2) or 
not (SBS-ATB) a GLP-2 analogue treatment during 3 weeks. Body weight, food intake were measured 
daily. Faeces, blood and intestine were collected for microbiome, hormonal and morphometric analyses.

Results: The SBS-GLP2 rats were less hyperphagic than the SBS rats (P<0.01), but regained similar weight, albeit with greater heterogeneity, which could to be related to the gut microbiome.Indeed, the rats with the best recovery appeared to have the greatest microbial diversity as well as increased jejunal hyperplasia. Furthermore, while weight gain was similar between SBS-ATB-GLP-2 and SBS-GLP-2 rats, GLP-2 treatment improved weight gain compared to SBS-ATB rats (P<0.05). Food intake of SBS-ATB-GLP-2 rats was improved compared to SBS-ATB (P>0.05). Finally, SBS-GLP-2 and SBS-ATB-GLP-2 rats had higher intestinal length compared to their respective control groups.

Conclusion: The gut microbiome may play a role in response to GLP-2 treatment and may provide an early prediction of the outcome of intestinal adaptation, which is critical for monitoring SBS disease.

Disclosure of Interest: None declared